Stockscreener 앱 받기
22.00
2.47%
0.53
시장 영업 전:
21.31
-0.69
-3.14%
전일 마감가:
$21.47
열려 있는:
$21.8
하루 거래량:
363.64K
Relative Volume:
1.66
시가총액:
$1.07B
수익:
-
순이익/손실:
$-82.83M
주가수익비율:
-11.46
EPS:
-1.92
순현금흐름:
$-72.22M
1주 성능:
+7.53%
1개월 성능:
-2.09%
6개월 성능:
-0.05%
1년 성능:
+53.74%
1일 변동 폭
$21.62
$22.68
1주일 범위
$20.30
$23.08
52주 변동 폭
$10.90
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
명칭
Enliven Therapeutics Inc
전화
720-647-8519
주소
6200 LOOKOUT ROAD, BOULDER
ELVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
22.00 | 1.07B | 0 | -82.83M | -72.22M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-13 | 개시 | BTIG Research | Buy |
| 2024-09-09 | 개시 | H.C. Wainwright | Buy |
| 2024-06-11 | 개시 | Robert W. Baird | Outperform |
| 2024-04-09 | 개시 | Mizuho | Buy |
| 2023-03-29 | 개시 | Jefferies | Buy |
Enliven Therapeutics Inc 주식(ELVN)의 최신 뉴스
Enliven Therapeutics (NASDAQ:ELVN) Shares Up 11.3%Here's Why - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Barclays PLC Acquires 42,012 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $524,706.00 in Stock - MarketBeat
Anish Patel, COO of Enliven Therapeutics, sells $685,868 in stock By Investing.com - Investing.com Nigeria
Anish Patel, COO of Enliven Therapeutics, sells $685,868 in stock - Investing.com
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 9.8%Time to Sell? - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,000 Shares - MarketBeat
Enliven's Early Data Stands Out From Peers (NASDAQ:ELVN) - Seeking Alpha
Enliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02 - MSN
(ELVN) Trading Advice - Stock Traders Daily
Jane Street Group LLC Sells 22,212 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Jane Street Group LLC Cuts Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Shares Up 7.6%Here's What Happened - MarketBeat
Enliven Therapeutics Inc (NASDAQ: ELVN) Stock Forecast: Bearish Sentiment Points To -75.56% Downside In 2025 - Stocks Register
Enliven Therapeutics CFO sells shares worth $94,474 - Investing.com India
Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 3,350 Shares of Stock - MarketBeat
Franklin Resources Inc. Invests $559,000 in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Barclays PLC Has $1.44 Million Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Barclays PLC Has $1.44 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Geode Capital Management LLC Boosts Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Geode Capital Management LLC Purchases 67,813 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 2.9%Here's Why - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Position Increased by State Street Corp - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Wellington Management Group LLP Raises Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Lord Abbett & CO. LLC Takes Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
The Manufacturers Life Insurance Company Increases Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
BTIG Research Initiates Coverage on Enliven Therapeutics (NASDAQ:ELVN) - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
When the Price of (ELVN) Talks, People Listen - Stock Traders Daily
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by BTIG Research - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 6.8%Should You Buy? - MarketBeat
Janus Henderson Group PLC Purchases 313,019 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by RA Capital Management L.P. - MarketBeat
Patient Square Capital LP Takes $2.31 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Walleye Capital LLC Takes $2.54 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Fmr LLC Boosts Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics CFO Benjamin Hohl sells $130,688 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics CFO Benjamin Hohl sells $130,688 in stock - Investing.com
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 3%What's Next? - MarketBeat
Ally Bridge Group NY LLC Takes $6 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Acuta Capital Partners LLC Sells 101,330 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 - Marketscreener.com
(ELVN) Investment Analysis - Stock Traders Daily
Enliven Therapeutics to Present at the Jefferies London Healthca - GuruFocus.com
Short Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Increases By 6.1% - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by First Turn Management LLC - MarketBeat
Robert W. Baird Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price - Defense World
Enliven Therapeutics Inc (ELVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):